FLUOCINONIDE


Trade Names	FLUOCINONIDE FLUOCINONIDE EMULSIFIED BASE LIDEX LIDEX-E VANOS
Synonyms	Fluocinolide Fluocinonide Fluocinonide emulsified base Lidex Lidex-e Metosyn Metosyn fapg NSC-101791 Vanos
Status
Molecule Category	Free-form
ATC	C05AA11 D07AC08
UNII	2W4A77YPAN
EPA CompTox	DTXSID8045307


InChI Key	WJOHZNCJWYWUJD-IUGZLZTKSA-N
Smiles	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
InChI	InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C26H32F2O7
Molecular Weight	494.53
AlogP	2.94
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	99.13
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	35.0

Mechanism of Action	Action	Reference
Glucocorticoid receptor agonist	AGONIST	PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	97.92-119.95

	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Cricetulus griseus	-	-	-	-	97.92-119.95

Target Conservation


Protein: Glucocorticoid receptor Description: Glucocorticoid receptor Organism : Homo sapiens P04150 ENSG00000113580

Resources	Reference
ChEBI	5109
ChEMBL	CHEMBL1501
DrugBank	DB01047
DrugCentral	1205
FDA SRS	2W4A77YPAN
Human Metabolome Database	HMDB0015181
Guide to Pharmacology	7078
PharmGKB	PA449664
PubChem	9642
SureChEMBL	SCHEMBL4262
ZINC	ZINC000003977978


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

FLUOCINONIDE

Structure

Physicochemical Descriptors

Pharmacology

Target Conservation

Related Entries

Cross References